Dopamine D4 Ligands and Models of Receptor Activation: 2-(4-Pyridin-2-ylpiperazin-1-ymethyl)-1H-benzimidazole and Related Heteroarylmethylarylpiperazines Exhibit a Substituent Effect Responsible for Additional Efficacy Tuning

Journal of Medicinal Chemistry

Volumn 47, Issue 9, 2004, Pages 2348-2355

  Stewart, Andrew O ^a   Cowart, Marlon D ^a   Moreland, Robert B ^a   Latshaw, Steve P ^a   Matulenko, Mark A ^a   Bhatia, Pramila A ^a   Wang, Xueqing ^a   Daanen, Jerome F ^a   Nelson, Sherry L ^a   Terranova, Marc A ^a   Namovic, Marian T ^a   Donnelly Roberts, Diana L ^a   Miller, Loan N ^a   Nakane, Masaki ^a   Sullivan, James P ^a   Brioni, Jorge D ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 PYRIDIN 2 YLPIPERAZIN 1 YLMETHYL) 1H BENZIMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; DOPAMINE 4 RECEPTOR; G PROTEIN COUPLED RECEPTOR; PHENYLPIPERAZINE; PIPERAZINE DERIVATIVE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; DOPAMINE 2 RECEPTOR; DRD4 PROTEIN, HUMAN; LIGAND; PYRIDINE DERIVATIVE;

ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; DRUG ACTIVITY; DRUG CONFORMATION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; PROTEIN DOMAIN; PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; BINDING COMPETITION; CELL LINE; CHEMISTRY; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN; RADIOASSAY; SYNTHESIS; THERMODYNAMICS;

BENZIMIDAZOLES; BINDING, COMPETITIVE; CELL LINE; HUMANS; LIGANDS; PIPERAZINES; PYRIDINES; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 1842628624     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0305669     Document Type: Article

References (62)

1. Bikker, J. A.; Trumpp-Kallmeyer, S.; Humblet, C. G-Protein Coupled Receptors: Models, Mutagenesis, and Drug Design. J. Med. Chem. 1998, 41, 2911-2927.
2. Perez, D. M. The Evolutionary Triumphant G-Protein-Coupled Receptor. Mol. Pharmacol. 2003, 63, 1202-1205.
3. Crossley, R. GPCRs come of age in San Diego. Drug Discovery Today 2003, 8, 19-20.
4. Kenakin, T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J. 2001, 15, 598-611.
5. (a) Adan, R. A. H.; Kas, M. J. H. Inverse agonism gains weight. Trends Pharmacol. Sci. 2003, 24, 315-321.
6. (b) Seifert, R.; Wenzel-Seifert, K. Constitutive activity of G-protein-coupled receptor: cause of disease and common property of wild type receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 2002, 366, 381-416.
7. Gether, U.; Koblika, B. K. G Protein-Coupled Receptors II. Mechanism of Agonist Activation. J. Biol. Chem. 1998, 273, 17979-17982.
8. (a) Simpson, M. M.; Ballesteros, J. A.; Chiappa, V.; Chen, J.; Suehiro, M.; Hartman, D. S.; Godel, T.; Snyder, L. A.; Sakmar, T. P.; Javitch, J. A. Dopamine D4/D2 Receptor Selectivity Is Determined by a Divergent Aromatic Microdomain Contained within the Second, Third, and Seventh Membrane-Spanning Segments. Mol. Pharmacol. 1999, 56, 116-1126.
9. 4 Dopamine Receptor Are Molecular Determinants of D4 Selective Pharmacology. Mol. Pharmacol. 2000, 57, 144-152.
10. (a) Martin, G. E.; Elgin, R. J., Jr.; Mathiasen, J. R.; Davis, C. B.; Kesslick, J. M.; Baldy, W. J.; Shank, R. P.; DiStefano, D. L.; Fedde, C. L.; Scott, M. K. Activity of Aromatic Substituted Phenylpiperazines Lacking Affinity for Dopamine Binding Sites in a Preclinical Test of Antipsychotic Efficacy. J. Med. Chem. 1989, 32, 1052-1056.
11. 2A receptor antagonists: LU-111995 and other potential new antipsychotics in development. Drugs Future 1998, 23, 191-204.
12. (c) Wustrow, D.; Belliotti, T.; Glase, S.; Kesten, S. R.; Johnson, D.; Colbry, N.; Rubin, R.; Blackburn, A.; Akunne, H.; Corbin, A.; Davis, M. D.; Georgic, L.; Whetzel, S.; Zoski, K.; Heffner, T.; Pugsley, T.; Wise, L. Aminopyrimidines with High Affinity for Both Serotonin and Dopamine Receptors. J. Med. Chem. 1998, 41, 760-771.
13. (d) Cervetto, L.; Demonthis, G. C.; Giannaccini, G.; Longoni, B.; Macchia, B.; Macchia, M.; Martinelli, A.; Orlandini, E. N-n-Propyl-Substituted 3-(Dimethylphenyl)piperidines Display Novel Discriminative Properties between Dopamine Receptor Subtypes: Synthesis and Receptor Binding Studies. J. Med. Chem. 1998, 41, 4933-4938.
14. (e) Cha, M. Y.; Choi, B. C.; Kang, H. K.; Pae, A. N.; Choi, K. I.; Cho, Y. S.; Koh, H. Y.; Lee, H.-Y.; Jung, D.; Kong, J. Y. Design and Synthesis of a Piperazinylalkylisoxazole Library for Subtype Selective Dopamine Receptor Ligands. Bioorg. Med. Chem. Lett. 2002, 12, 1327-1330.
15. Shi, L.; Javitch, J. A. The Binding Site of Aminergic G-Protein-Coupled Receptors: The Transmembrane Segments and Second Extracellular Loop. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 437-467
16. Ji, T. H.; Grossmann, M.; Ji, I. G Protein-Coupled Receptors. I. Diversity of Receptor-Ligand Interactions. J. Biol. Chem. 1998, 273, 17299-17302.
17. (a) Nicolaou, K. C.; Pfefferkorn, J. A.; Roecker, A. J.; Cao, G.-Q.; Barluenga, S.; Mitchell, H. J. Natural Product-like Combinatorial Libraries Based on Privledged Structures. 1. General Principles and Solid Phase Synthesis of Benzopyrans. J. Am. Chem. Soc. 2000, 122, 9939-9953.
18. (b) Muller, G. Medicinal chemistry of target family-directed masterkeys. Drug Discovery Today 2003, 8, 681-691.
19. Emilien, G.; Maloteaux, J.-M.; Geurts, M.; Hoogenberg, K.; Cragg, S. Dopamine receptors-physiological understanding to therapeutic intervention potential. Pharmacol. Ther. 1999, 84, 133-156.
20. 4 receptor: a controversial therapeutic target. Drugs Future 2000, 25, 587-611.
21. 4 Receptor. J. Pharmacol. Exp. Ther. 1997, 283, 636-647.
22. 4.4 receptor. Br. J. Pharmacol. 1998, 124, 889-896.
23. Lober, S.; Hubner, H.; Utz, W.; Gmeiner, P. Rational Based Efficacy Tunning of Selective Dopamine D4 Receptor Ligands Leading to the Complete Antagonist 2-[4-(4-Chlorophenyl)-piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 213). J. Med. Chem. 2001, 44, 2691-2694.
24. (a) Hsieh, G. C.; Hollingsworth, P. R.; Martino, B.; Chang, R.; Terranova, M. A.; O'Neill, A. B.; Lynch, J. J.; Moreland, R. B.; Donnelly-Roberts, D.; Kolasa, T.; Mikusa, J. P.; McVey, J. M.; Marsh, K. C.; Sullivan, J. P.; Brioni, J. D. Central Mechanisms Regulating Penile Erection in Conscious Rats: The Dopaminergic Systems Related to the Pro-erectile Effect of Apomorphine. J. Pharmacol. Exp. Ther. 2004, 308, 330-338.
25. (b) Brioni, J. D.; Moreland, R. B.; Cowart, M.; Hsieh, G. C.; Stewart, A. O.; Hedlund, P.; Donnelly-Roberts, D. L.; Nakane, M.; Lynch, J.; Kolasa, T.; Polakowski, J. S.; Osinski, M. A.; Marsh, K.; Andersson, K.-E.; Sullivan, J. P. ABT-724, a novel and selective dopamine D4 receptor agonist, induces penile erections in conscious rats. Soc. Neurosci. Abstr. 2003, 29, 573.15 (program number).
26. Cowart, M.; Latshaw, S. P.; Bhatia, P.; Daanen, J. F.; Rohde, J.; Nelson, S. L.; Patel, M.; Kolasa, T.; Nakane, M.; Uchic, M. E.; Miller, L. N.; Terranova, M. A.; Chang, R.; Donnelly-Roberts, D. L.; Namovic, M. T.; Hollingsworth, P. R.; Martino, B. R.; Lynch, J. J., III; Sullivan, J. P.; Hsieh, G. C.; Moreland, R. B.; Brioni, J. D.; Stewart, A. O. The Discovery of ABT-724, A Dopaminergic Agent with a Novel Mode of Action for the Treatment of Erectile Dysfunction. J. Med. Chem., submitted (manuscript JM030505A and personal communication).
27. (a) Zorn, S. H.; Jackson, E.; Johnson, C.; Lewis, J.; Fliri, A. CP-226-269 is a selective dopamine D4 receptor agonist. Soc. Neurosci. Abstr. 1997, 23, 685.
28. 4 Agonists. J. Med. Chem. 1997, 40, 1771-1772.
29. (c) Powell, S. B.; Paulus, M. P.; Hartman, D. S.; Godel, T.; Geyer, M. A. RO-10-5824 is a selective dopamine D4 receptor agonist that increases novel object exploration in C57 mice. Neuropharmacology 2003, 44, 473-481.
30. (a) Houk, K. N.; Leach, A. G.; Kim, S. P.; Zhang, X. Binding Affinities of Host-Guest, Protein-Ligand, and Protein-Transition-State Complexes. Angew. Chem., Int. Ed. 2003, 42, 4872-4897.
31. (b) Gilli, P.; Ferretti, V.; Gilli, G.; Borea, P. A. Enthalpy-Entropy Compensation in Drug-Receptor Binding. J. Phys. Chem. 1994, 98, 1515-1518.
32. (c) Raffa, R. B.; Porreca, F. Thermodynamic Analysis of the Drug-Receptor Interaction. Life Sci. 1989, 44, 245-258.
33. Baker, R.; Curtis, N. R.; Kulagowski, J. J.; Leeson, P. D.; Ridgill, M. P.; Smith, A. L. Pyrrolo-Pyridine Derivatives. U.S. Patent, 5,622,950, April 22, 1997.
34. (a) Gopalakrishnan, S. M.; Moreland, R. B.; Kofron, J. L.; Helfrich, R. J.; Gubbins, E.; McGowen, J.; Masters, J. N.; Donnelly-Roberts, D.; Brioni, J. D.; Burns, D. J.; Warrior, U. A cell-based microarrayed compound screening format for identifying agonists of G-protein-coupled receptors. Anal. Biochem. 2003, 321, 192-201.
35. (b) Coward, P.; Chan, S. D. H.; Wada, H. G.; Humphries, G. M.; Conklin, B. R. Chimeric G Proteins Allow a High-Throughput Signaling Assay of G-Coupled Receptors. Anal. Biochem. 1999, 270, 242-248.
36. 4 Receptor Variants. J. Neurochem. 1995, 65, 1157-1165.
37. (a) Hansch, C.; Leo, A. Exploring QSAR Fundamental and Applications in Chemistry and Biology; Professional Reference Book Series; American Chemical Society; Washington, DC, 1995; Chapter 13.
38. (b) Chen, X.; Wang, W. The use of bioisoteric groups in lead optimization. Annu. Rep. Med. Chem. 2003, 38, 333-346.
39. (c) Martin, Y. C. A Practioner's Perspective of the Role of Quantitative Structure-Activity Analysis in Medicinal Chemistry. J. Med. Chem. 1981, 24, 229-237.
40. (a) Colquoun, D. Binding, gating, affinity, and efficacy: The interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br. J. Pharmacol. 1998, 125, 924-947.
41. (b) Leff, P. The two-state model of receptor activation. Trends Pharmacol. Sci. 1995, 16, 89-97.
42. (c) Leff, P.; Scaramellini, C.; Law, C.; McKechnie, K. A three-state model of agonist action. Trends Pharmacol. Sci. 1997, 18, 355-362.
43. Williams, L. T.; Lefkowitz, R. J. Slowly Reversible Binding of Catecholamine to a Nucleotide-Sensitive State of the β-Adrenergic Receptor. J. Biol. Chem. 1977, 252, 7207-7213.
44. 2 Dopamine Receptor/G Protein Interaction. J. Biol. Chem. 2001,276, 28667-28675.
45. 3 Receptor Structure. J. Pharmacol. Exp. Ther. 2000, 295, 274-283.
46. 35S] Binding. J. Pharmacol. Exp. Ther. 1998, 285, 119-126.
47. Newman-Tancredi, A.; Audinot-Bouchez, V.; Gobert, A.; Millan, M. J. Noradrenaline and adrenaline are high affinity agonists at dopamine D4 receptors. Eur. J. Pharmacol. 1997, 319, 379-383.
48. (a) Lahti, R. A.; Figur, L. M.; Piercey, M. F.; Ruppel, P. L.; Evans, D. L. Intrinsic Activity Determinations at the Dopamine D2 Guanine Nucleotide-Binding Protein-Coupled Receptor: Utilization of Receptor State Binding Affinities. Mol. Pharmacol. 1992, 42, 432-438.
49. 2C Receptors. Synapse 2000, 35, 144-150.
50. 4.4 receptors. Eur. J. Pharmacol. 1996, 301, R11-R13.
51. (a) Yeagle, P. L.; Albert, A. D. A Conformational Trigger for Activation of a G protein by a G Protein-Coupled Receptor. Biochem. 2003, 42, 1365-1368.
52. (b) Betts, J. B.; Sternberg, M. J. E. An analysis of conformational changes on protein-protein association: implications for predictive docking. Protein Eng. 1999, 12, 271-283.
53. 4 antagonists. Prog. NeuroPsychopharmacol. Biol. Psychiatry 2002, 26, 219-226.
54. Walsh, C. Enzymatic Reaction Mechanisms; W. H. Freeman and Company: San Fransisco, 1979; pp 33-35.
55. (a) Eliel, E. L.; Wilen, S. H. Stereochemistry of Organic Compounds; John Wiley & Sons Inc.: New York, 1994; Chapter X, pp 647-655.
56. (b) Seeman, J. I. Effect of Conformational Change on Reactivity in Organic Chemistry. Evaluations, Applications, and Extensions of Curtin-Hammett/Winstein-Holness Kinetics. Chem. Rev. 1983, 83, 83-134.
57. (a) Rome, L. H.; Lands, W. E. M. Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by antiinflammatory drugs. Proc. Natl. Acad. Sci. U.S.A. 1975, 72, 4863-4865.
58. (b) Riendeau, D.; Percival, M. D.; Boyce, S.; C. Brideau, C.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans, J.; Falgueyret, J.-P.; Ford-Hutchinson, A. W.; Gordon, R.; Greig, G.; Gresser, M.; Guay, J.; Kargman, S.; Leger, S.; Mancini, J. A.; O'Neill, G.; Ouellet, M.; Rodger, I. W.; Therien, M.; Wang, Z.; Webb, J. K.; Wong, E.; Xu, L.; Young, R. N.; Zamboni, R.; Prasit, P.; Chan, C.-C. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br. J. Pharmacol. 1997, 121, 105-117.
59. αo fusion protein expressed in Sf9 cells. FEBS Lett. 2003, 545, 155-160.
60. 16 the optimal tool for fishing ligands of orphan G-protein-coupled receptors? Trends Pharmacol. Sci. 2001, 22, 560-564.
61. Kenakin, T. Predicting Therapeutic Value in the Lead Optimization Phase of Drug Discovery. Nat. Rev. Drug Discovery 2003, 2, 429-438.
62. 2L. Soc. Neurosci. Abstr. 2002, 28, 830.9 (program number).